FindTrial
Sign In

Study on Multi-Omics Characteristics of Pulmonary Nodules Based on Disease-Syndrome-Body Integration and the Mechanism of Traditional Chinese Medicine Syndrome Differentiation and Treatment

Study on Multi-Omics Characteristics of Pulmonary Nodules Based on Disease-Syndrome-Body Integration and the Mechanism of Traditional Chinese Medicine Syndrome Differentiation and Treatment

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025002637
Enrollment
Unknown
Registered
2025-12-30
Start date
2026-02-01
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary nodules

Interventions

Sanjie Fang Group:Participants received the Sanjie Fang decoction (Nodule-Resolving Herbal Formula) orally, with the following composition per dose: Ingredients:Peach Kernel 10g
Safflower 9g
Chinese Angelica 15g
Hirsute Shiny Bugleweed Herb 10g
Common Selfheal Spike 15g
Thunberg Fritillary Bulb 10g
Chlorite Schist 15g
Finger Citron 9g
Cinnamon Twig 10g
Turmeric Root Tuber 9g Preparation: Each dose was decocted into 2 bags (100ml/bag). Administration: Taken warm tw
Placebo Group:The placebo was prepared by diluting the Sanjie Fang decoction 20-fold with added food coloring flavoring and bittering agents to match the appearance taste and odor of the original form

Sponsors

The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Traditional Chinese Medicine)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria:1.Fulfilling Western diagnostic criteria for pulmonary nodules and classified as low- intermediate- or high-risk;2.Age 18–70 years;3.Voluntary participation with signed informed consent.

Exclusion criteria

Exclusion criteria: Exclusion Criteria:1.Patients with concurrent tuberculosis sarcoidosis or other infectious diseases; 2.Patients with severe primary diseases of cardiovascular hepatic renal or hematopoietic systems or malignancy diagnosed within 5 years;3.Patients with psychiatric disorders (e.g. mania schizophrenia) or other conditions compromising study compliance;4.Women planning pregnancy currently pregnant or lactating; 5.Patients allergic to study-involved Chinese herbs or with a history of polypharmacy hypersensitivity.

Design outcomes

Primary

MeasureTime frame
Malignant signs;Rate of change of cross-sectional area;Diameter change;—

Secondary

MeasureTime frame
Risk conversion rate;Changes in average diameter and average cross-sectional area;Malignant probability;—

Countries

China

Contacts

Public ContactMaosheng Xu

The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Traditional Chinese Medicine)

xums166@zcmu.edu.cn+86 136 0580 8040

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026